SCHEMBL1619909

SCHEMBL1619909

COc1cc(C=O)cc(O[Si](C(C)C)(C(C)C)C(C)C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 5/20 0.44
CYP1B1 Q16678 5/20 0.44
ALDH1A1 P00352 2/20 0.41
CYP2A6 P11509 1/20 0.41
CYP1A2 P05177 3/20 0.39
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
USP2 O75604 1/20 0.38
PKM P14618 1/20 0.38
NQO2 P16083 5/20 0.38
ABL1 P00519 3/20 0.38
BCR P11274 3/20 0.38
ESR1 P03372 2/20 0.38
TTR P02766 2/20 0.38
ABCB1 P08183 2/20 0.38
ALOX5 P09917 2/20 0.38
CYP19A1 P11511 2/20 0.38
PTGS2 P35354 2/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17203693 0.85 ALDH1A1 (0.52) CYP1A1CYP1B1ALDH1A1CYP2A6CYP1A2
SCHEMBL23906958 0.85 ALDH1A1 (0.52) CYP1A1CYP1B1ALDH1A1CYP2A6CYP1A2
SCHEMBL1620823 0.83 ALDH1A3 (0.34) CYP2A6KDM4E
SCHEMBL228003 0.81 CYP1A1 (0.64) CYP1A1CYP1B1ALDH1A1CYP2A6CYP1A2
Water SCHEMBL28227114 0.79 CYP1A1 (0.61) CYP1A1CYP1B1ALDH1A1CYP2A6CYP1A2
SCHEMBL1621200 0.78 EGFR (0.33) EGFR
SCHEMBL1663786 0.77 ALDH1A1 (0.58) CYP1A1CYP1B1ALDH1A1CYP2A6CYP1A2
SCHEMBL18428478 0.77 ALDH1A1 (0.33) ALDH1A1
SCHEMBL22779349 0.77 ALDH1A3 (0.55) CYP1A1CYP1B1ALDH1A1CYP2A6CYP1A2
SCHEMBL17203257 0.77 ALDH1A1 (0.42) CYP1A1CYP1B1ALDH1A1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194046-B1 Triazolone derivative EISAI R&D MAN CO LTD (JP) 2012-05-09 EP disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
EP-2194046-A1 Triazolone derivative Eisai R&D Management Co., Ltd. (JP) 2010-06-09 EP disclosed
EP-2000465-A1 TRIAZOLONE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190783-A1 TRIAZOLONE DERIVATIVES H1-0, H1-10, H1-2 CYP1A1 29/4885CYP1B1 41/4885ALDH1A1 701/4885
US-20110112109-A1 TRIAZOLONE DERIVATIVES H1-10, H1-0, H1-2 CYP1A1 33/4885CYP1B1 55/4885ALDH1A1 905/4885
US-20080015199-A1 Triazolone derivatives F3, F12, F2 CYP1A1 25/4885CYP1B1 31/4885ALDH1A1 710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.